Hennion & Walsh Asset Management Inc. Raises Stock Position in Arcturus Therapeutics Holdings Inc. $ARCT

Hennion & Walsh Asset Management Inc. grew its stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 23.8% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 346,207 shares of the biotechnology company’s stock after purchasing an additional 66,528 shares during the quarter. Hennion & Walsh Asset Management Inc.’s holdings in Arcturus Therapeutics were worth $2,327,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Sumitomo Mitsui Trust Group Inc. increased its position in shares of Arcturus Therapeutics by 12.9% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,288,935 shares of the biotechnology company’s stock valued at $17,671,000 after buying an additional 262,347 shares during the period. Heartland Advisors Inc. purchased a new stake in Arcturus Therapeutics in the first quarter worth about $1,976,000. Amova Asset Management Americas Inc. lifted its holdings in Arcturus Therapeutics by 12.9% in the first quarter. Amova Asset Management Americas Inc. now owns 2,288,935 shares of the biotechnology company’s stock worth $17,648,000 after buying an additional 262,347 shares during the period. Diversify Wealth Management LLC bought a new stake in Arcturus Therapeutics during the 1st quarter valued at approximately $133,000. Finally, Hsbc Holdings PLC boosted its position in Arcturus Therapeutics by 175.7% during the 4th quarter. Hsbc Holdings PLC now owns 66,131 shares of the biotechnology company’s stock valued at $402,000 after acquiring an additional 42,148 shares in the last quarter. 94.54% of the stock is owned by hedge funds and other institutional investors.

Arcturus Therapeutics Price Performance

Shares of Arcturus Therapeutics stock opened at $7.52 on Wednesday. Arcturus Therapeutics Holdings Inc. has a 1 year low of $5.50 and a 1 year high of $24.17. The firm has a market cap of $213.72 million, a price-to-earnings ratio of -2.27 and a beta of 2.39. The company has a 50-day moving average of $6.75 and a 200 day moving average of $7.39.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.84) EPS for the quarter, topping the consensus estimate of ($1.00) by $0.16. Arcturus Therapeutics had a negative net margin of 317.62% and a negative return on equity of 46.54%. The business had revenue of $2.96 million for the quarter, compared to analyst estimates of $3.11 million. On average, equities analysts anticipate that Arcturus Therapeutics Holdings Inc. will post -3.55 EPS for the current year.

Wall Street Analysts Forecast Growth

ARCT has been the subject of several research reports. Wall Street Zen raised Arcturus Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday. Weiss Ratings restated a “sell (d-)” rating on shares of Arcturus Therapeutics in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $24.25.

Arcturus Therapeutics Profile

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.